
Journal of Medicinal Chemistry p. 1650 - 1662 (1992)
Update date:2022-07-29
Topics:
Wissner, A.
Carroll, M. L.
Green, K. E.
Kerwar, S. S.
Pickett, W. C.
et al.
A series of aryl phosphoglyceride (3, 19-61) and bis-aryl phosphate (67-135) antagonists of platelet activating factor (PAF) were prepared.A group of four bifunctional phosphorus reagents (5a-c and 7) were developed that allowed the preparation of these aryl phosphates in which the position of aromatic substitution can be varied.These compounds were examined for their ability to inhibit PAF-induced platelet aggregation of rabbit platelets.Selected compounds were also evaluated for their ability to displace <3H>PAF from its receptor on rabbit platelets.These in vitro data were compared to similar data obtained for a number of known PAF antagonists.The compounds were evaluated in vivo, in both the mouse and rabbit, for their ability to prevent death induced by a lethal challenge of PAF.The relationships between the biological activity and the nature, lipophilicity, and position of substituents of the aromatic rings were studied.Compound 105 (CL 184005) has been selected to undergo further development as a potential therapeutic agent for the treatment of septic shock in man.
View Morejintan yufan Medicine Raw materials Co.,Ltd.(expird)
Contact:86-519-82808282
Address:6th,Jincheng Huangzhuang
website:http://www.mingchem.com/en/index
Contact:0519-85170101-802
Address:Fifth Floor,B of Beihua Buliding,520 Road of Science and Education City,Changwu middle road NO.801,Wujin District,Changzhou,Jiangsu province
Fujian Wanke Pharmaceutical Co., LTD.
Contact:+86-598-5026002
Address:Economic development zone,jiangle county
chengdu firsterchem Pharmaceutical Co., Ltd.
Contact:028-66825849
Address:chengdu
Sanming Coffer Fine Chemical Industrial Co., Ltd
website:http://www.cofferxm.com/
Contact:+86-598-5853979
Address:Jin-sha Yuan Chuang-ye Park,Hi-Tech Development Zone,Sanming City P.R.China
Doi:10.1135/cccc19920188
(1992)Doi:10.1016/j.tetlet.2012.09.091
(2012)Doi:10.1016/j.bmcl.2018.04.024
(2018)Doi:10.1016/j.bmcl.2012.09.006
(2012)Doi:10.1016/j.tetlet.2012.03.105
(2012)Doi:10.1021/cg300342a
(2012)